Therapy Development for Epidermolysis Bullosa
Open Access
- 27 April 2021
- book chapter
- Published by IntechOpen
Abstract
Although rare genodermatoses such as Epidermolysis bullosa have received more attention over the last years, no approved treatment options targeting causal mutations are currently available. Still, such diseases can be devastating, in some cases even associated with life-threatening secondary manifestations. Therefore, developing treatments that target disease-associated complications along with causal therapies remains the focus of current research efforts, in order to increase patient’s quality of life and potentially their life expectancy. Epidermolysis bullosa is a genodermatosis that is caused by mutations in either one of 16 genes, predominantly encoding structural components of the skin and mucosal epithelia that are crucial to give these barrier organs physical and mechanical resilience to stress. The genetic heterogeneity of the disease is recapitulated in the high variability of phenotypic expressivity observed, ranging from minor and localized blistering to generalized erosions and wound chronification, rendering certain subtypes a systemic disease that is complicated by a plethora of secondary manifestations. During the last decades, several studies have focused on developing treatments for EB patients and significant progress has been made, as reflected by numerous publications, patents, and registered trials available. Overall, strategies range from causal to symptom-relieving approaches, and include gene, RNA and cell therapies, as well as drug developments based on biologics and small molecules. In this chapter, we highlight the most recent and promising approaches that are currently being investigated in order to provide effective treatments for patients with epidermolysis bullosa in the future.Keywords
This publication has 100 references indexed in Scilit:
- Trans-splicing correction of tau isoform imbalance in a mouse model of tau mis-splicingHuman Molecular Genetics, 2013
- A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial ImmunityScience, 2012
- Progress towards genetic and pharmacological therapies for keratin genodermatoses: current perspective and future promiseExperimental Dermatology, 2012
- Basic mechanisms of itchClinical & Experimental Allergy, 2011
- Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: Molecular bases for EGFR-targeted therapyPathology - Research and Practice, 2011
- Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinomaOncogene, 2011
- The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapyJournal of Clinical Investigation, 2009
- A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapyJournal of Clinical Investigation, 2008
- Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleasesProceedings of the National Academy of Sciences, 2008
- Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cellsNature Medicine, 2006